Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection

Aaron M. Cook, Christian N. Ramsey, Craig Martin, Thomas Pittman

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The emergence of multidrug-resistant bacteria as the cause of ventriculoperitoneal shunt infections is a disconcerting phenomenon that often requires the use of alternative antimicrobials due to resistance against commonly used agents. The following is a case report describing the successful treatment of a ventriculoperitoneal shunt infection caused by a heteroresistant strain of Staphylococcus aureus with linezolid. Linezolid may have utility in treating pediatric CNS infections due to its tolerability, excellent blood-brain barrier penetration, and activity against multiple resistant Gram-positive organisms such as S. aureus, vancomycin-resistant Enterococcus faecium and Streptococcus pneumoniae.

Original languageEnglish
Pages (from-to)102-104
Number of pages3
JournalPediatric Neurosurgery
Issue number2
StatePublished - Mar 2005


  • Gram-positive organisms
  • Heteroresistance
  • Linezolid
  • Vancomycin
  • Ventriculitis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection'. Together they form a unique fingerprint.

Cite this